Skip to search formSkip to main contentSkip to account menu

Herceptin

Known as: Herceptin® 
National Institutes of Health

Related topics

Related topics

3 relations
erbB-2 Receptortrastuzumab 22 MG/ML Injectable Solution [Herceptin]

Broader (1)

trastuzumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.
Acquired resistance to Herceptin is a major clinical problem in the treatment of HER2-overexpressing breast cancer. Understanding… 
Highly Cited
2006
Highly Cited
2006
A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions
The orphan receptor tyrosine kinase ErbB2 is activated by each of the EGFR family members upon ligand binding. However… 
Review
2005
Review
2005
Central nervous system metastases in breast cancer patients administered trastuzumab.
Highly Cited
2005
Highly Cited
2005
In vitro and in vivo Effects of Combination of Trastuzumab (Herceptin) and Tamoxifen in Breast Cancer
SummaryExtensive interactions between estrogen receptor α (ERα) and HER2 signaling pathways have been described. Using BT-474… 
Highly Cited
2004
Highly Cited
2004
Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes
Purpose: Numerous examples from animal models and clinical trials showed that HER-2-derived peptides are naturally processed as a… 
2004
2004
Herceptin-Geldanamycin Immunoconjugates
The efficacy of monoclonal antibodies (mAbs) as single agents in targeted cancer therapy has proven to be limited. Arming mAbs… 
Highly Cited
2002
Highly Cited
2002
Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol.
Cyclin D1 is downstream of erbB2 and is required for erbB2 transformation. Here we report thatcyclin D1 functions are essential… 
Highly Cited
2001
Highly Cited
2001
Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.
Review
2001
Review
2001
Dose Scheduling – Herceptin®
Preclinical and phase I/II studies of Herceptin® demonstrated a dose-related, non-linear pharmacokinetic profile. The results of… 
2001
2001
Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study.
BACKGROUND In patients with HER2-positive metastatic breast cancer (MBC), combined treatment of herceptin (H) and chemotherapy… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)